ODAC Applauds Effort, But Votes Against Y-mAbs’ I-Omburtamab In Neuroblastoma

 
• By Derrick Gingery
  
Neuroblastoma mountain
ODAC members said more work was needed before I-omburtamab could be approved. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers